Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 556 to 570 of 1362 results for social care

  1. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development Reference number: GID-TA11019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Support a quality standard

    reference panel membership Meetings in public Consultations GPs and primary care NICE training and development opportunities By...

  3. Support a quality standard

    reference panel membership Meetings in public Consultations GPs and primary care NICE training and development opportunities By...

  4. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413

    In development Reference number: GID-TA11488 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  5. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

    In development Reference number: GID-TA11498 Expected publication date:  29 April 2026

    Technology appraisal guidance
    In development

  6. Guide to the processes of technology appraisal (PMG19)

    This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes

  7. Interim methods guide for developing good practice guidance (PMG15)

    This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance

  8. Meetings in public

    Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.

  9. Implementation help and advice

    NICE work with the NHS, patients and carers, healthcare professionals and organisations to help put our guidance into practice.

  10. Meetings in public

    Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.

  11. Learning disabilities: health checks and action plans (IND265)

    This indicator covers the percentage of patients on the learning disability register who received a learning disability health check and had a completed health action plan in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM249

    General practice indicators suitable for use in QOF
    Published
    31 October 2023

  12. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  13. Upadacitinib for treating giant cell arteritis [ID6299]

    In development Reference number: GID-TA11330 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. NICE and virtual wards

    We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.

  15. About indicators

    Our indicators measure outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.